https://orcid.org/0000-0003-1564-9825
Key Points
28 loci/proteins were found to be associated with VTE recurrence risk.
The genomic architecture of VTE recurrence risk varies based on the initial clinical presentation.
Subjects:
Thrombosis and Hemostasis
Abstract
Venous thromboembolism (VTE) is a frequent (annual incidence of 1-2 per 1000 individuals) and potentially life-threatening (case-fatality rate up to 10%) disease. VTE is associated with serious short-term and long-term complications, including a recurrence rate approaching 20% within 5 years. Anticoagulant therapy, the mainstay of VTE treatment, drastically reduces the risk of early VTE recurrence, but it exposes patients to a substantial risk of bleeding. We analyzed the genomic architecture of VTE recurrence using data from 6355 patients across 8 cohorts (including 1775 recurrences), enriched by subgroup analyses, according to sex and clinical manifestation of first VTE, which led to the identification of 28 molecular markers. Through genome-wide association studies, we identified 1 locus associated with VTE recurrence, GPR149/MME. Among all variants known to be associated with first VTE, KNG1, and FGG were associated with recurrence. Additionally, Mendelian randomization analyses identified 7 proteins as risk factors for recurrence: elevated plasma levels of coagulation factor XI, coagulation factor VIII, von Willebrand factor, histo-blood group ABO system transferase, and Golgi membrane protein 2; and decreased levels of proprotein convertase subtilisin/kexin 9 and pro–interleukin-16. Subgroup analyses revealed 18 molecular determinants associated with VTE recurrence, with notable differences between subgroups. For example, the exonic variant SLC4A1 p.Glu40Lys was significantly associated in patients who experienced pulmonary embolism but showed no effect in those with deep vein thrombosis. These findings emphasize the role of specific genetic loci and protein pathways in influencing VTE recurrence and provide valuable insights into potential therapeutic targets. Further research is needed to clarify the biological mechanisms driving these associations.
Subjects:
Thrombosis and Hemostasis
References
1.
Raskob
GE
, Angchaisuksiri
P
, Blanco
AN
, et al. Thrombosis: a major contributor to global disease burden
. Arterioscler Thromb Vasc Biol
. 2014
;34
(11
):2363
-2371
.2.
Cohen
AT
, Agnelli
G
, Anderson
FA
, et al. Venous thromboembolism (VTE) in Europe. the number of VTE events and associated morbidity and mortality
. Thromb Haemost
. 2007
;98
(4
):756
-764
.3.
Stevens
SM
, Woller
SC
, Kreuziger
LB
, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report
. Chest
. 2021
;160
(6
):e545
-e608
.4.
Delluc
A
, Tromeur
C
, Le Ven
F
, et al. Current incidence of venous thromboembolism and comparison with 1998: a community-based study in Western France
. Thromb Haemost
. 2016
;116
(5
):967
-974
.5.
Couturaud
F
, Sanchez
O
, Pernod
G
, et al. Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: the PADIS-PE randomized clinical trial
. JAMA
. 2015
;314
(1
):31
-40
.6.
Khan
F
, Rahman
A
, Carrier
M
, et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis
. BMJ
. 2019
;366
:l4363
.7.
Lecumberri
R
, Alfonso
A
, Jiménez
D
, et al. Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism
. Thromb Haemost
. 2013
;110
(4
):834
-843
.8.
Tagalakis
V
, Patenaude
V
, Kahn
SR
, Suissa
S
. Treatment patterns of venous thromboembolism in a real-world population: the Q-VTE study cohort
. Thromb Res
. 2014
;134
(4
):795
-802
.9.
Konstantinides
SV
, Torbicki
A
, Agnelli
G
, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)
. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism
. Eur Heart J
. 2014
;35
(43
):3033
-3069
.10.
Tosetto
A
, Iorio
A
, Marcucci
M
, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH)
. J Thromb Haemost
. 2012
;10
(6
):1019
-1025
.11.
Eichinger
S
, Heinze
G
, Jandeck
LM
, Kyrle
PA
. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model
. Circulation
. 2010
;121
(14
):1630
-1636
.12.
Timp
JF
, Braekkan
SK
, Lijfering
WM
, et al. Prediction of recurrent venous thrombosis in all patients with a first venous thrombotic event: the Leiden thrombosis recurrence risk prediction model (L-TRRiP)
. PLoS Med
. 2019
;16
(10
):e1002883
.13.
De Winter
MA
, Büller
HR
, Carrier
M
, et al. Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score
. Eur Heart J
. 2023
;44
(14
):1231
-1244
.14.
Rodger
MA
, Le Gal
G
, Anderson
DR
, et al. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study
. BMJ
. 2017
;356
:j1065
.15.
Kyrle
P
, Eischer
L
, Šinkovec
H
, Eichinger
S
, Eichinger
S
. Factor XI and recurrent venous thrombosis: an observational cohort study
. J Thromb Haemost
. 2019
;17
(5
):782
-786
.16.
Hoke
M
, Kyrle
PA
, Minar
E
, et al. Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism
. Thromb Haemost
. 2005
;94
(4
):787
-790
.17.
Kyrle
PA
, Minar
E
, Hirschl
M
, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism
. N Engl J Med
. 2000
;343
(7
):457
-462
.18.
Edvardsen
MS
, Hindberg
K
, Hansen
E-S
, et al. Plasma levels of von Willebrand factor and future risk of incident venous thromboembolism
. Blood Adv
. 2021
;5
(1
):224
-232
.19.
Rodger
MA
, Kahn
SR
, Wells
PS
, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy
. Can Med Assoc J
. 2008
;179
(5
):417
-426
.20.
Christiansen
SC
, Cannegieter
SC
, Koster
T
, Vandenbroucke
JP
, Rosendaal
FR
. Thrombophilia, clinical factors, and recurrent venous thrombotic events
. JAMA
. 2005
;293
(19
):2352
-2361
.21.
Baglin
T
, Luddington
R
, Brown
K
, Baglin
C
. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study
. Lancet
. 2003
;362
(9383
):523
-526
.22.
Prandoni
P
, Noventa
F
, Ghirarduzzi
A
, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients
. Haematologica
. 2007
;92
(2
):199
-205
.23.
Lutsey
PL
, Zakai
NA
. Epidemiology and prevention of venous thromboembolism
. Nat Rev Cardiol
. 2023
;20
(4
):248
-262
.24.
Couturaud
F
, Leroyer
C
, Tromeur
C
, et al. Factors that predict thrombosis in relatives of patients with venous thromboembolism
. Blood
. 2014
;124
(13
):2124
-2130
.25.
Klarin
D
, Busenkell
E
, Judy
R
, et al. Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease
. Nat Genet
. 2019
;51
(11
):1574
-1579
.26.
Thibord
F
, Klarin
D
, Brody
JA
, et al. Cross-ancestry investigation of venous thromboembolism genomic predictors
. Circulation
. 2022
;146
(16
):1225
-1242
.27.
de Haan
HG
, van Hylckama Vlieg
A
, Germain
M
, et al. Genome-wide association study identifies a novel genetic risk factor for recurrent venous thrombosis
. Circ Genomic Precision Med
. 2018
;11
(2
):e001827
.28.
Munsch
G
, Goumidi
L
, van Hylckama Vlieg
A
, et al. Association of ABO blood groups with venous thrombosis recurrence in middle-aged patients: insights from a weighted Cox analysis dedicated to ambispective design
. BMC Med Res Methodol
. 2023
;23
(1
):99
.29.
Mägi
R
, Morris
AP
. GWAMA: software for genome-wide association meta-analysis
. BMC Bioinformatics
. 2010
;11
(1
):288
.30.
Gusev
A
, Ko
A
, Shi
H
, et al. Integrative approaches for large-scale transcriptome-wide association studies
. Nat Genet
. 2016
;48
(3
):245
-252
.31.
Giambartolomei
C
, Vukcevic
D
, Schadt
EE
, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics
. PLoS Genet
. 2014
;10
(5
):e1004383
.32.
Burgess
S
, Davey Smith
G
, Davies
NM
, et al. Guidelines for performing Mendelian randomization investigations: update for summer 2023
. Wellcome Open Res
. 2019
;4
:186
.33.
Hemani
G
, Haycock
P
, Zheng
J
, et al. TwoSampleMR R Package (v0.5.7). Zenodo
; 2023
Accessed 6 November 2023. .34.
Ferkingstad
E
, Sulem
P
, Atlason
BA
, et al. Large-scale integration of the plasma proteome with genetics and disease
. Nat Genet
. 2021
;53
(12
):1712
-1721
.35.
Pietzner
M
, Wheeler
E
, Carrasco-Zanini
J
, et al. Mapping the proteo-genomic convergence of human diseases
. Science
. 2021
;374
(6569
):eabj1541
.36.
Sun
BB
, Chiou
J
, Traylor
M
, et al. Plasma proteomic associations with genetics and health in the UK Biobank
. Nature
. 2023
;622
(7982
):329
-338
.37.
Chen
Y
, Lu
T
, Pettersson-Kymmer
U
, et al. Genomic atlas of the plasma metabolome prioritizes metabolites implicated in human diseases
. Nat Genet
. 2023
;55
(1
):44
-53
.38.
van der Harst
P
, Verweij
N
. Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease
. Circ Res
. 2018
;122
(3
):433
-443
.39.
Temprano-Sagrera
G
, Sitlani
CM
, Bone
WP
, et al. Multi-phenotype analyses of hemostatic traits with cardiovascular events reveal novel genetic associations
. J Thromb Haemost
. 2022
;20
(6
):1331
-1349
.40.
Rauluseviciute
I
, Riudavets-Puig
R
, Blanc-Mathieu
R
, et al. JASPAR 2024: 20th anniversary of the open-access database of transcription factor binding profiles
. Nucleic Acids Res
. 2024
;52
(D1
):D174
-D182
.41.
Ren
A
, Gan
Q
, Han
W
, Gong
D
, Cai
J
, Qu
X
. Endothelial GATA5 positively regulates angiogenesis via cathepsin S-mediated Angpt2/Flk1 and MMP2/9 signaling pathways
. Biochem Biophys Res Commun
. 2022
;609
:111
-118
.42.
Cantor
AB
. Thrombocytopoiesis. In: Hoffman
R
, Benz
EJ
, Silberstein
LE
, eds. Hematology
. 7th ed. 2018
:334
-349
.43.
Iruela-Arispe
ML
, Luque
A
, Lee
N
. Thrombospondin modules and angiogenesis
. Int J Biochem Cell Biol
. 2004
;36
(6
):1070
-1078
.44.
Rühle
F
, Witten
A
, Barysenka
A
, et al. Rare genetic variants in SMAP1, B3GAT2, and RIMS1 contribute to pediatric venous thromboembolism
. Blood
. 2017
;129
(6
):783
-790
.45.
Leung
LL
. Role of thrombospondin in platelet aggregation
. J Clin Invest
. 1984
;74
(5
):1764
-1772
.46.
Godin
O
, Dufouil
C
, Maillard
P
, et al. White matter lesions as a predictor of depression in the elderly: the 3C-Dijon study
. Biol Psychiatry
. 2008
;63
(7
):663
-669
.47.
Ward
LD
, Kellis
M
. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants
. Nucleic Acids Res
. 2012
;40
(Database issue
):D930
-D934
.48.
Bezerra
OCL
, Rodger
M
, Munsch
G
, et al. Sex-specific DNA methylation marks associated with sex-biased risk of recurrence in unprovoked venous thromboembolism
. J Thromb Haemost
. 2025
;23
(4
):1379
-1392
.49.
Konstantinides
SV
, Meyer
G
, Becattini
C
, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC)
. Eur Respir J
. 2019
;54
(3
):1901647
.50.
Zhu
T
, Martinez
I
, Emmerich
J
. Venous thromboembolism: risk factors for recurrence
. ATVB
. 2009
;29
(3
):298
-310
.51.
Flinterman
LE
, van Hylckama Vlieg
A
, Rosendaal
FR
, Cannegieter
SC
. Body height, mobility, and risk of first and recurrent venous thrombosis
. J Thromb Haemost
. 2015
;13
(4
):548
-554
.52.
Zöller
B
, Ohlsson
H
, Sundquist
J
, Sundquist
K
. Family history of venous thromboembolism (VTE) and risk of recurrent hospitalization for VTE: a nationwide family study in Sweden
. J Thromb Haemost
. 2014
;12
(3
):306
-312
.53.
Eichinger
S
, Weltermann
A
, Mannhalter
C
, et al. The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism
. Arch Intern Med
. 2002
;162
(20
):2357
-2360
.54.
Meijer
K
, Schulman
S
. The absence of “minor” risk factors for recurrent venous thromboembolism: a systematic review of negative predictive values and negative likelihood ratios
. J Thromb Haemost
. 2009
;7
(10
):1619
-1628
.55.
Perez Botero
J
, Wysokinski
WE
, Patnaik
MM
, et al. Do incident and recurrent venous thromboembolism risks truly differ between heterozygous and homozygous factor V Leiden carriers? A retrospective cohort study
. Eur J Intern Med
. 2016
;30
:77
-81
.56.
Gailani
D
, Gruber
A
. Targeting factor XI and factor XIa to prevent thrombosis
. Blood
. 2024
;143
(15
):1465
-1475
.57.
Sabater-Lleal
M
, Martinez-Perez
A
, Buil
A
, et al. A genome-wide association study identifies KNG1 as a genetic determinant of plasma factor XI level and activated partial thromboplastin time
. Arterioscler Thromb Vasc Biol
. 2012
;32
(8
):2008
-2016
.58.
Goumidi
L
, Thibord
F
, Wiggins
KL
, et al. Association between ABO haplotypes and the risk of venous thrombosis: impact on disease risk estimation
. Blood
. 2021
;137
(17
):2394
-2402
.59.
Onsaker
AL
, Arntzen
AY
, Trégouët
D-A
, et al. Histo-blood group ABO system transferase plasma levels and risk of future venous thromboembolism: the HUNT study
. Blood
. 2025
;145
(22
):2656
-2665
.60.
Bapat
J
, Yamamoto
TM
, Woodruff
ER
, et al. CASC4/GOLM2 drives high grade serous carcinoma anoikis resistance through the recycling of EGFR
. Cancer Gene Ther
. 2024
;31
(2
):300
-310
.61.
3C Study Group
. Vascular factors and risk of dementia: design of the three-city study and baseline characteristics of the study population
. Neuroepidemiology
. 2003
;22
(6
):316
-325
.62.
Mootoosamy
C
, Kondyli
M
, Serfaty
SA
, et al. IL16 and factor V gene variations are associated with asparaginase-related thrombosis in childhood acute lymphoblastic leukemia patients
. Pharmacogenomics
. 2023
;24
(4
):199
-206
.63.
de Souza
VH
, de Alencar
JB
, Tiyo
BT
, et al. Association of functional IL16 polymorphisms with cancer and cardiovascular disease: a meta-analysis
. Oncotarget
. 2020
;11
(36
):3405
-3417
.64.
Richmond
J
, Tuzova
M
, Cruikshank
W
, Center
D
. Regulation of cellular processes by interleukin-16 in homeostasis and cancer
. J Cell Physiol
. 2014
;229
(2
):139
-147
.65.
He
H
, Ding
M
, Zhu
Y
, et al. Interleukin-16/STAT6 recruits CBP/p300 to upregulate TIMP-3 and promote atherosclerotic plaque stability
. bioRxiv
. Preprint posted online 24 May 2023
.66.
Grönberg
C
, Bengtsson
E
, Fredrikson
GN
, et al. Human carotid plaques with high levels of interleukin-16 are associated with reduced risk for cardiovascular events
. Stroke
. 2015
;46
(10
):2748
-2754
.67.
Grönberg
C
, Asciutto
G
, Persson
A
, et al. Endarterectomy patients with elevated levels of circulating IL-16 have fewer cardiovascular events during follow-up
. Cytokine
. 2016
;85
:137
-139
.68.
Badimon
L
, Vilahur
G
. Thrombosis formation on atherosclerotic lesions and plaque rupture
. J Intern Med
. 2014
;276
(6
):618
-632
.69.
Puteri
MU
, Azmi
NU
, Kato
M
, Saputri
FC
. PCSK9 promotes cardiovascular diseases: recent evidence about its association with platelet activation-induced myocardial infarction
. Life (Basel)
. 2022
;12
(2
):190
.70.
Marston
NA
, Gurmu
Y
, Melloni
GEM
, et al. The effect of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition on the risk of venous thromboembolism
. Circulation
. 2020
;141
(20
):1600
-1607
.71.
Wang
H
, Wang
Q
, Wang
J
, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency is protective against venous thrombosis in mice
. Sci Rep
. 2017
;7
(1
):14360
.72.
Kheirkhah
A
, Schachtl-Riess
JF
, Lamina
C
, et al. Meta-GWAS on PCSK9 concentrations reveals associations of novel loci outside the PCSK9 locus in White populations
. Atherosclerosis
. 2023
;386
:117384
.73.
Graham
SE
, Clarke
SL
, Wu
K-HH
, et al. The power of genetic diversity in genome-wide association studies of lipids
. Nature
. 2021
;600
(7890
):675
-679
.74.
Loya
H
, Kalantzis
G
, Cooper
F
, Palamara
PF
. A scalable variational inference approach for increased mixed-model association power
. Nat Genet
. 2025
;57
(2
):461
-468
.75.
Mishra
A
, Malik
R
, Hachiya
T
, et al. Stroke genetics informs drug discovery and risk prediction across ancestries
. Nature
. 2022
;611
(7934
):115
-123
.76.
Aragam
KG
, Jiang
T
, Goel
A
, et al. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants
. Nat Genet
. 2022
;54
(12
):1803
-1815
.77.
Hartiala
JA
, Han
Y
, Jia
Q
, et al. Genome-wide analysis identifies novel susceptibility loci for myocardial infarction
. Eur Heart J
. 2021
;42
(9
):919
-933
.78.
Stewart
LK
, Sarmiento
EJ
, Kline
JA
. Statin use is associated with reduced risk of recurrence in patients with venous thromboembolism
. Am J Med
. 2020
;133
(8
):930
-935.e8
.79.
Li
R
, Yuan
M
, Yu
S
, et al. Effect of statins on the risk of recurrent venous thromboembolism: a systematic review and meta-analysis
. Pharmacol Res
. 2021
;165
:105413
.80.
Biedermann
JS
, Kruip
MJHA
, van der Meer
FJ
, et al. Rosuvastatin use improves measures of coagulation in patients with venous thrombosis
. Eur Heart J
. 2018
;39
(19
):1740
-1747
.81.
Chang
W
, Sheu
C
, Liu
K
, Shen
JH
, Yen
MC
, Kuo
PL
. Identification of mutations in SLC4A1, GP1BA and HFE in a family with venous thrombosis of unknown cause by next-generation sequencing
. Exp Ther Med
. 2018
;16
(5
):4172
-4180
.82.
Zhong
J
, Dong
J
, Ruan
W
, Duan
X
. Potential theranostic roles of SLC4 molecules in human diseases
. IJMS
. 2023
;24
(20
):15166
.83.
Douketis
JD
, Kearon
C
, Bates
S
, Duku
EK
, Ginsberg
JS
. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism
. JAMA
. 1998
;279
(6
):458
-462
.84.
Ten Cate
V
, Prochaska
JH
, Schulz
A
, et al. Protein expression profiling suggests relevance of noncanonical pathways in isolated pulmonary embolism
. Blood
. 2021
;137
(19
):2681
-2693
.85.
Owzar
K
, Li
Z
, Cox
N
, Jung
S-H
. Power and sample size calculations for SNP association studies with censored time-to-event outcomes
. Genet Epidemiol
. 2012
;36
(6
):538
-548
.86.
Kearon
C
, Ageno
W
, Cannegieter
SC
, et al. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH
. J Thromb Haemost
. 2016
;14
(7
):1480
-1483
.87.
Zon
B
, Sekar
A
, Clapham
K
, et al. Clonal hematopoiesis and venous thromboembolism in the UK Biobank [abstract]
. Blood
. 2023
;142
(suppl 1
):568
.88.
Rosendaal
F
. Venous thrombosis: a multicausal disease
. Lancet
. 1999
;353
(9159
):1167
-1173
.89.
Schulman
S
, Lindmarker
P
, Holmström
M
, et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months
. J Thromb Haemost
. 2006
;4
(4
):734
-742
.© 2025 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
2025
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal